441 related articles for article (PubMed ID: 22983389)
1. PI3K and Akt as molecular targets for cancer therapy: current clinical outcomes.
Pal I; Mandal M
Acta Pharmacol Sin; 2012 Dec; 33(12):1441-58. PubMed ID: 22983389
[TBL] [Abstract][Full Text] [Related]
2. The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients.
Martelli AM; Evangelisti C; Chiarini F; McCubrey JA
Oncotarget; 2010 Jun; 1(2):89-103. PubMed ID: 20671809
[TBL] [Abstract][Full Text] [Related]
3. Targeting the phosphatidylinositol 3-kinase signaling pathway in breast cancer.
Hernandez-Aya LF; Gonzalez-Angulo AM
Oncologist; 2011; 16(4):404-14. PubMed ID: 21406469
[TBL] [Abstract][Full Text] [Related]
4. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway.
Polivka J; Janku F
Pharmacol Ther; 2014 May; 142(2):164-75. PubMed ID: 24333502
[TBL] [Abstract][Full Text] [Related]
5. The PI3K/AKT Pathway as a Target for Cancer Treatment.
Mayer IA; Arteaga CL
Annu Rev Med; 2016; 67():11-28. PubMed ID: 26473415
[TBL] [Abstract][Full Text] [Related]
6. Targeting PI3K/Akt signal transduction for cancer therapy.
He Y; Sun MM; Zhang GG; Yang J; Chen KS; Xu WW; Li B
Signal Transduct Target Ther; 2021 Dec; 6(1):425. PubMed ID: 34916492
[TBL] [Abstract][Full Text] [Related]
7. Targeting the PI3K/AKT/mTOR pathway: biomarkers of success and tribulation.
Owonikoko TK; Khuri FR
Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714559
[TBL] [Abstract][Full Text] [Related]
8. New development of inhibitors targeting the PI3K/AKT/mTOR pathway in personalized treatment of non-small-cell lung cancer.
Sun Z; Wang Z; Liu X; Wang D
Anticancer Drugs; 2015 Jan; 26(1):1-14. PubMed ID: 25304988
[TBL] [Abstract][Full Text] [Related]
9. Inhibitors of the PI3K/Akt/mTOR pathway: new hope for breast cancer patients.
Ghayad SE; Cohen PA
Recent Pat Anticancer Drug Discov; 2010 Jan; 5(1):29-57. PubMed ID: 19751211
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of constitutively activated phosphoinositide 3-kinase/AKT pathway enhances antitumor activity of chemotherapeutic agents in breast cancer susceptibility gene 1-defective breast cancer cells.
Yi YW; Kang HJ; Kim HJ; Hwang JS; Wang A; Bae I
Mol Carcinog; 2013 Sep; 52(9):667-75. PubMed ID: 22488590
[TBL] [Abstract][Full Text] [Related]
11. Targeting the PI3K/AKT signaling pathway in anticancer research: a recent update on inhibitor design and clinical trials (2020-2023).
Sabbah DA; Hajjo R; Bardaweel SK; Zhong HA
Expert Opin Ther Pat; 2024 Mar; 34(3):141-158. PubMed ID: 38557273
[TBL] [Abstract][Full Text] [Related]
12. Quinazoline based small molecule exerts potent tumour suppressive properties by inhibiting PI3K/Akt/FoxO3a signalling in experimental colon cancer.
Qazi AK; Hussain A; Khan S; Aga MA; Behl A; Ali S; Singh SK; Taneja SC; Shah BA; Saxena AK; Mondhe DM; Hamid A
Cancer Lett; 2015 Apr; 359(1):47-56. PubMed ID: 25554016
[TBL] [Abstract][Full Text] [Related]
13. Targeting the PI3K/Akt signaling pathway in gastric carcinoma: A reality for personalized medicine?
Singh SS; Yap WN; Arfuso F; Kar S; Wang C; Cai W; Dharmarajan AM; Sethi G; Kumar AP
World J Gastroenterol; 2015 Nov; 21(43):12261-73. PubMed ID: 26604635
[TBL] [Abstract][Full Text] [Related]
14. Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers.
Coussy F; El Botty R; Lavigne M; Gu C; Fuhrmann L; Briaux A; de Koning L; Dahmani A; Montaudon E; Morisset L; Huguet L; Sourd L; Painsec P; Chateau-Joubert S; Larcher T; Vacher S; Melaabi S; Salomon AV; Marangoni E; Bieche I
J Hematol Oncol; 2020 Feb; 13(1):13. PubMed ID: 32087759
[TBL] [Abstract][Full Text] [Related]
15. Maximising the potential of AKT inhibitors as anti-cancer treatments.
Brown JS; Banerji U
Pharmacol Ther; 2017 Apr; 172():101-115. PubMed ID: 27919797
[TBL] [Abstract][Full Text] [Related]
16. Targeting PI3K in cancer: mechanisms and advances in clinical trials.
Yang J; Nie J; Ma X; Wei Y; Peng Y; Wei X
Mol Cancer; 2019 Feb; 18(1):26. PubMed ID: 30782187
[TBL] [Abstract][Full Text] [Related]
17. The Current Status and Future Role of the Phosphoinositide 3 Kinase/AKT Signaling Pathway in Urothelial Cancer: An Old Pathway in the New Immunotherapy Era.
Liu ST; Hui G; Mathis C; Chamie K; Pantuck AJ; Drakaki A
Clin Genitourin Cancer; 2018 Apr; 16(2):e269-e276. PubMed ID: 29199023
[TBL] [Abstract][Full Text] [Related]
18. PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside.
Alzahrani AS
Semin Cancer Biol; 2019 Dec; 59():125-132. PubMed ID: 31323288
[TBL] [Abstract][Full Text] [Related]
19. PI3K/Akt/mTOR pathway inhibitors in cancer: a perspective on clinical progress.
Wu P; Hu YZ
Curr Med Chem; 2010; 17(35):4326-41. PubMed ID: 20939811
[TBL] [Abstract][Full Text] [Related]
20. The PI3K/Akt/mTOR signaling pathway in gastric cancer; from oncogenic variations to the possibilities for pharmacologic interventions.
Baghery Saghchy Khorasani A; Pourbagheri-Sigaroodi A; Pirsalehi A; Safaroghli-Azar A; Zali MR; Bashash D
Eur J Pharmacol; 2021 May; 898():173983. PubMed ID: 33647255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
